Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Authors
Keywords
Intratumour heterogeneity, Neoantigens, Genomic instability, Immune surveillance, Immune checkpoint inhibitors
Journal
SEMINARS IN CANCER BIOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-23
DOI
10.1016/j.semcancer.2021.02.013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- Genomic basis for RNA alterations in cancer
- (2020) Claudia Calabrese et al. NATURE
- Pan-cancer analysis of whole genomes
- (2020) NATURE
- The evolutionary history of 2,658 cancers
- (2020) Moritz Gerstung et al. NATURE
- The repertoire of mutational signatures in human cancer
- (2020) Ludmil B. Alexandrov et al. NATURE
- Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution
- (2020) Saioa López et al. NATURE GENETICS
- HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
- (2020) J.H. Shim et al. ANNALS OF ONCOLOGY
- Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy
- (2020) Alejandro Jiménez-Sánchez et al. NATURE GENETICS
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
- (2020) Khalid AbdulJabbar et al. NATURE MEDICINE
- Measuring Intratumoral Heterogeneity of Immune Repertoires
- (2020) Diana Vladimirovna Yuzhakova et al. Frontiers in Oncology
- PD-1 inhibitors: Do they have a future in the treatment of glioblastoma?
- (2020) Mustafa Khasraw et al. CLINICAL CANCER RESEARCH
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy
- (2020) Katherine I Zhou et al. CLINICAL CANCER RESEARCH
- Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
- (2020) Shani Ben Dori et al. LUNG CANCER
- Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
- (2020) Haiying Ding et al. PLoS One
- Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
- (2020) Qu Zhang et al. Cancer Discovery
- Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
- (2020) Giuseppe Lombardi et al. Cancers
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
- (2019) Jacob H. Rasmussen et al. BRITISH JOURNAL OF CANCER
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Cancer stemness, intratumoral heterogeneity, and immune response across cancers
- (2019) Alex Miranda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
- (2019) David W. Vredevoogd et al. CELL
- Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts
- (2019) Daniel Kazdal et al. Journal of Thoracic Oncology
- UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
- (2019) Yochai Wolf et al. CELL
- The Immunoscore: Colon Cancer and Beyond
- (2019) Helen K Angell et al. CLINICAL CANCER RESEARCH
- Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study
- (2019) Melina Arnold et al. LANCET ONCOLOGY
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- (2019) Aparna R. Parikh et al. NATURE MEDICINE
- Neoantigen quality, not quantity
- (2019) Nicholas McGranahan et al. Science Translational Medicine
- An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine
- (2019) Hiroyuki Yamamoto et al. SEMINARS IN ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive mutability of colorectal cancers in response to targeted therapies
- (2019) Mariangela Russo et al. SCIENCE
- An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
- (2019) Yin Wu et al. Science Translational Medicine
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- Are liquid biopsies a surrogate for tissue EGFR testing?
- (2018) J W Goldman et al. ANNALS OF ONCOLOGY
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- (2018) Matthew H. Bailey et al. CELL
- Human T Cell Development, Localization, and Function throughout Life
- (2018) Brahma V. Kumar et al. IMMUNITY
- Chromosomal instability drives metastasis through a cytosolic DNA response
- (2018) Samuel F. Bakhoum et al. NATURE
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
- (2018) Magdalena Witkowska et al. Journal of Immunology Research
- NKG2D: A Master Regulator of Immune Cell Responsiveness
- (2018) Felix M. Wensveen et al. Frontiers in Immunology
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
- (2018) Sandra P. D’Angelo et al. JAMA Oncology
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas
- (2018) Chaoting Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- High response rate to PD-1 blockade in desmoplastic melanomas
- (2018) Zeynep Eroglu et al. NATURE
- Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
- (2018) Natalie Galanina et al. Cancer Immunology Research
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- Rejection of immunogenic tumor clones is limited by clonal fraction
- (2018) Ron S Gejman et al. eLife
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
- (2018) Corentin Richard et al. CLINICAL CANCER RESEARCH
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
- (2017) Giovanni Germano et al. NATURE
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Cytoplasmic chromatin triggers inflammation in senescence and cancer
- (2017) Zhixun Dou et al. NATURE
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- cGAS is essential for the antitumor effect of immune checkpoint blockade
- (2017) Hua Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- Chromosomal Instability as a Driver of Tumor Heterogeneity and Evolution
- (2017) Samuel F. Bakhoum et al. Cold Spring Harbor Perspectives in Medicine
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
- (2017) Christine Koch et al. Frontiers in Immunology
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Ipilimumab and Bevacizumab in Glioblastoma
- (2016) T. Carter et al. CLINICAL ONCOLOGY
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
- (2016) Luc G.T. Morris et al. Oncotarget
- Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
- (2016) Yu Zhang et al. JAMA Oncology
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
- (2015) T.-M. Kim et al. CLINICAL CANCER RESEARCH
- Translational Implications of Tumor Heterogeneity
- (2015) M. Jamal-Hanjani et al. CLINICAL CANCER RESEARCH
- T cells in the control of organ-specific autoimmunity
- (2015) Jeffrey A. Bluestone et al. JOURNAL OF CLINICAL INVESTIGATION
- Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma
- (2015) Oren Litvin et al. MOLECULAR CELL
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
- (2015) Noemi Andor et al. NATURE MEDICINE
- Subclonal diversification of primary breast cancer revealed by multiregion sequencing
- (2015) Lucy R Yates et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- Evolutionary Determinants of Cancer
- (2015) M. Greaves Cancer Discovery
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients
- (2014) Marta Pestrin et al. Molecular Oncology
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis
- (2014) Peter S. Linsley et al. PLoS One
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
- (2014) E. C. de Bruin et al. SCIENCE
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- Lessons from the Cancer Genome
- (2013) Levi A. Garraway et al. CELL
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Promotion and prevention of autoimmune disease by CD8+ T cells
- (2013) David M. Gravano et al. JOURNAL OF AUTOIMMUNITY
- Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
- (2013) Marco Gerlinger et al. JOURNAL OF PATHOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Digital Genomic Quantification of Tumor-Infiltrating Lymphocytes
- (2013) H. S. Robins et al. Science Translational Medicine
- Dissection of T-cell Antigen Specificity in Human Melanoma
- (2012) R. S. Andersen et al. CANCER RESEARCH
- The Life History of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
- (2012) J. S. Wilmott et al. MOLECULAR CANCER THERAPEUTICS
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
- (2012) Luis A. Diaz Jr et al. NATURE
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Expression of tumour-specific antigens underlies cancer immunoediting
- (2012) Michel DuPage et al. NATURE
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
- (2012) Z.-Y. Chen et al. ONCOLOGIST
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
- (2011) N. J. Birkbak et al. CANCER RESEARCH
- Mechanisms of tolerance
- (2011) Jeffrey A. Bluestone IMMUNOLOGICAL REVIEWS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Natural Killer Cell Education and Tolerance
- (2010) Mark T. Orr et al. CELL
- The patterns and dynamics of genomic instability in metastatic pancreatic cancer
- (2010) Peter J. Campbell et al. NATURE
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- (2010) Shinichi Yachida et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive assessment of T-cell receptor -chain diversity in T cells
- (2009) H. S. Robins et al. BLOOD
- Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
- (2009) Y. Kuang et al. CLINICAL CANCER RESEARCH
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis
- (2009) Xavier Sastre-Garau et al. JOURNAL OF PATHOLOGY
- Autoimmunity: increasing suspects in the CD4+ T cell lineup
- (2009) Matthew T Palmer et al. NATURE IMMUNOLOGY
- Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways
- (2008) J. D. Coudert et al. BLOOD
- Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
- (2008) P. J. Campbell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
- (2008) C. G. Mullighan et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now